| pubmed-article:8823333 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8823333 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:8823333 | lifeskim:mentions | umls-concept:C0146224 | lld:lifeskim |
| pubmed-article:8823333 | lifeskim:mentions | umls-concept:C1527249 | lld:lifeskim |
| pubmed-article:8823333 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:8823333 | lifeskim:mentions | umls-concept:C0205464 | lld:lifeskim |
| pubmed-article:8823333 | lifeskim:mentions | umls-concept:C0444889 | lld:lifeskim |
| pubmed-article:8823333 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:8823333 | lifeskim:mentions | umls-concept:C1521801 | lld:lifeskim |
| pubmed-article:8823333 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:8823333 | pubmed:dateCreated | 1996-10-30 | lld:pubmed |
| pubmed-article:8823333 | pubmed:abstractText | Topotecan is a specific inhibitor of topoisomerase I. Preclinical data have indicated that topoisomerase I inhibitors demonstrate more efficacy and have a greater therapeutic index with prolonged continuous exposure. The feasibility of this concept in humans using a 21-day continuous infusion of topotecan has been reported. We conducted a phase II study of this 21-day continuous topotecan administration schedule in patients with locally advanced, unresectable or metastatic colorectal cancer. | lld:pubmed |
| pubmed-article:8823333 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8823333 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8823333 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8823333 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8823333 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8823333 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8823333 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8823333 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:8823333 | pubmed:issn | 0732-183X | lld:pubmed |
| pubmed-article:8823333 | pubmed:author | pubmed-author:StoterGG | lld:pubmed |
| pubmed-article:8823333 | pubmed:author | pubmed-author:LoosWW | lld:pubmed |
| pubmed-article:8823333 | pubmed:author | pubmed-author:van der... | lld:pubmed |
| pubmed-article:8823333 | pubmed:author | pubmed-author:PlantingA SAS | lld:pubmed |
| pubmed-article:8823333 | pubmed:author | pubmed-author:VerweijJJ | lld:pubmed |
| pubmed-article:8823333 | pubmed:author | pubmed-author:HudsonII | lld:pubmed |
| pubmed-article:8823333 | pubmed:author | pubmed-author:CreemersG JGJ | lld:pubmed |
| pubmed-article:8823333 | pubmed:author | pubmed-author:SchellensJ... | lld:pubmed |
| pubmed-article:8823333 | pubmed:author | pubmed-author:GerritsC JCJ | lld:pubmed |
| pubmed-article:8823333 | pubmed:author | pubmed-author:HarteveldMM | lld:pubmed |
| pubmed-article:8823333 | pubmed:author | pubmed-author:de... | lld:pubmed |
| pubmed-article:8823333 | pubmed:author | pubmed-author:van... | lld:pubmed |
| pubmed-article:8823333 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8823333 | pubmed:volume | 14 | lld:pubmed |
| pubmed-article:8823333 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8823333 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8823333 | pubmed:pagination | 2540-5 | lld:pubmed |
| pubmed-article:8823333 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:8823333 | pubmed:meshHeading | pubmed-meshheading:8823333-... | lld:pubmed |
| pubmed-article:8823333 | pubmed:meshHeading | pubmed-meshheading:8823333-... | lld:pubmed |
| pubmed-article:8823333 | pubmed:meshHeading | pubmed-meshheading:8823333-... | lld:pubmed |
| pubmed-article:8823333 | pubmed:meshHeading | pubmed-meshheading:8823333-... | lld:pubmed |
| pubmed-article:8823333 | pubmed:meshHeading | pubmed-meshheading:8823333-... | lld:pubmed |
| pubmed-article:8823333 | pubmed:meshHeading | pubmed-meshheading:8823333-... | lld:pubmed |
| pubmed-article:8823333 | pubmed:meshHeading | pubmed-meshheading:8823333-... | lld:pubmed |
| pubmed-article:8823333 | pubmed:meshHeading | pubmed-meshheading:8823333-... | lld:pubmed |
| pubmed-article:8823333 | pubmed:meshHeading | pubmed-meshheading:8823333-... | lld:pubmed |
| pubmed-article:8823333 | pubmed:meshHeading | pubmed-meshheading:8823333-... | lld:pubmed |
| pubmed-article:8823333 | pubmed:meshHeading | pubmed-meshheading:8823333-... | lld:pubmed |
| pubmed-article:8823333 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8823333 | pubmed:articleTitle | Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer. | lld:pubmed |
| pubmed-article:8823333 | pubmed:affiliation | Department of Medical Oncology, Rotterdom Cancer Institute, The Netherlands. | lld:pubmed |
| pubmed-article:8823333 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8823333 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8823333 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8823333 | lld:pubmed |
